Search

Displaying results 8311 - 8320 of 8547 in total
  1. Drug

    Brecanavir

    go.drugbank.com/drugs/DB04887
    Investigational

    The decision was based on issues regarding the formulation of the drug.

  2. Drug

    MVA-SARS-2-S

    go.drugbank.com/drugs/DB16432
    Investigational

    MVA is a highly attenuated poxvirus vector[A226603] that has a high-level of biological safety due to its quality of being a non-replicating virus in mammalian hosts[L30458] and is used to develop vaccines

  3. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    [A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148]

  4. Drug

    Faxeladol

    go.drugbank.com/drugs/DB20529
    Investigational

    Faxeladol has a monoisotopic molecular weight of 233.18 Da.

  5. Drug

    Flizasertib

    go.drugbank.com/drugs/DB21613
    Investigational

    Flizasertib has a monoisotopic molecular weight of 271.11 Da.

  6. Drug

    AP5346

    go.drugbank.com/drugs/DB04992
    Investigational

    AP5346 is designed to target a diaminocyclohexane platinum (Pt) moiety to tumors through pH-sensitive linkage to a 25 kDa hydroxypropylmethacrylamide polymer. It is being pursued by Access Pharmaceuticals, Inc.

  7. Drug

    GLB-001

    go.drugbank.com/drugs/DB32795
    Investigational

    GLB-001 is a orally bioavailable molecular glue degrader targeting casein kinase 1 alpha (CK1a).

  8. Drug

    Ferrous aspartate

    go.drugbank.com/drugs/DB13220
    Experimental

    It is also used for dying of fabric or leather and as a wood preservative.

  9. Drug

    Afimkibart

    go.drugbank.com/drugs/DB18718
    Investigational

    RVT-3101 is a fully human monoclonal antibody targeting vascular endothelial growth inhibitor, also known as TNF-like ligand 1A (TL1A) and TNF superfamily member 15.

  10. Drug

    Tifcemalimab

    go.drugbank.com/drugs/DB18914
    Investigational

    Tifcemalimab is under investigation in clinical trial NCT06095583 (Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell